Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part I)

Qing Liu, Karl E. Peace

Research output: Contribution to journalArticlepeer-review

Abstract

<p> It is well-recognized that the COVID-19 pandemic has hit many ongoing clinical trials hard in many ways, including but not limited to: <ol> <li> Government interventions including suppression and non-pharmaceutical interventions (NPIs) such as social distancing, lockdown, or quarantine. </li> <li> Supplies of study medications and availability of healthcare professionals and facilities for clinical and/or laboratory evaluations, treatment administration according to scheduled clinical visits typically specified in Table 1 of study protocols. </li> </ol></p>
Original languageAmerican English
JournalLinkedIn
StatePublished - Mar 31 2020

Disciplines

  • Biostatistics
  • Environmental Public Health
  • Epidemiology
  • Public Health

Fingerprint

Dive into the research topics of 'Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part I)'. Together they form a unique fingerprint.

Cite this